With Positive Boceprevir Data In Hand, Merck Prepares NDA Submission
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The race to bring the first oral protease inhibitor to market for the treatment of hepatitis C shows no signs of abating. Merck announced positive data from two Phase III trials evaluating boceprevir Aug. 4, along with plans to initiate a rolling NDA submission and complete the filing by the end of the year. That puts boceprevir on about the same regulatory trajectory as Vertex/Johnson & Johnson's telaprevir, which Vertex has said it will file in the second half of the year
You may also be interested in...
Telaprevir ILLUMINATE Study May Light The Way To Shorter Hep C Treatment
Strong positive data from ILLUMINATE, the second of three Phase III studies of Vertex's hepatitis C treatment telaprevir to report, add evidence to the case the company is building for a response-guided regimen that could cut treatment time in half for many patients, potentially increasing compliance rates and leading to more cures
Telaprevir ILLUMINATE Study May Light The Way To Shorter Hep C Treatment
Strong positive data from ILLUMINATE, the second of three Phase III studies of Vertex's hepatitis C treatment telaprevir to report, add evidence to the case the company is building for a response-guided regimen that could cut treatment time in half for many patients, potentially increasing compliance rates and leading to more cures
Vertex Advances Toward Telaprevir Approval
The first Phase III results for the hepatitis C direct-acting antiviral give the firm reason to be confident.